Short answer
Zymeworks Inc. (ZYME) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 7.01 (Regulation FD Disclosure). $250M upfront from Royalty Pharma via royalty monetization of Ziihera (zanidatamab), structured as a royalty sale + non-recourse term loan at subsidiary level.
Zymeworks Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $250M upfront from Royalty Pharma via royalty monetization of Ziihera (zanidatamab), structured as a royalty sale + non-recourse term loan at subsidiary level
- Total repayment obligation: ~$481.3M by Dec 31, 2042 maturity; early repayment by Dec 31, 2033 reduces obligation to $412.5M, implying ~65–93% effective cost of capital
- Zymeworks retains 70% of Ziihera royalties during loan term; 100% reverts once loan repaid: all milestone payments also fully retained by Zymeworks
- Non-recourse structure limits lender claims to SPV collateral only; no recourse against Zymeworks Inc. or Zymeworks BC assets beyond pledged equity interests
- Change-of-control triggers default and immediate repayment: materially constrains M&A optionality for acquirers
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 covers material financial obligations: key details (amount, rate, maturity, purpose) would determine investor impact
- Filing text cut off before disclosing any substantive terms of the off-balance sheet arrangement
Item 7.01 · Regulation FD Disclosure
- Standard Reg FD safe harbor language only: no financial data, operational updates, or material information disclosed in this excerpt
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zymeworks Inc. 8-K filings
Get the next ZYME 8-K as it lands
Follow ZYME for push alerts, or ask the research agent what this filing means.